ProGenis Pharmaceuticals is thrilled to announce that we have been awarded funding from the Medical Research Future Fund (MRFF) under the Targeted Translation Research Accelerator (TTRA) program for Diabetes and Cardiovascular Disease, delivered by MTPConnect.
This prestigious grant will support the advancement of our novel RNA therapeutic candidate, PGP-011, designed to improve insulin sensitivity and overall health outcomes for people living with type 2 diabetes.
This funding marks a significant milestone in our mission to develop next-generation, small synthetic RNA-based therapeutics for chronic diseases and will accelerate our path toward first-in-human trials. We are honoured to be among the eight Australian companies selected for the TTRA Drugs Stream, following a rigorous three-stage competitive process. Our warmest congratulations also go out to all other recipients.
Founded in Perth, ProGenis Pharmaceuticals (ProGenis) is a biotechnology startup co-founded by Professor Marvin H. Caruthers and Professor Rakesh N. Veedu, building on six years of pioneering R&D at Murdoch University, the Perron Institute, and the University of Colorado Boulder. The company is focused on developing innovative thiomorpholino chemistry-based RNA therapeutics that offer enhanced stability, specificity, and therapeutic potential.
We are grateful for the guidance of Professor Bu Yeap and Professor Girish Dwivedi as our clinical chairs, and deeply appreciate our dedicated scientific team for their relentless efforts to drive our development programs. ProGenis is also working closely with community and consumer organisations, including Diabetes WA, to advance PGP-011 toward clinical translation.
We sincerely thank MTPConnect and the TTRA team for their support in accelerating homegrown innovation and strengthening Australia’s translational research ecosystem. Above all, we thank everyone who has supported us on this journey.
At ProGenis, we remain committed to improving the health and wellbeing of people through innovative RNA-based therapeutics.